Navigation Links
Kosan's Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
Date:8/19/2007

HAYWARD, Calif., Aug. 6 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN) today announced that Pfizer Inc. has initiated a Phase 1 clinical trial of motilin receptor agonist PF-04548043, formerly KOS-2187, a selective and potent motilin receptor agonist being developed for the treatment of gastroesophageal reflux disease (GERD) and potentially other gastrointestinal (GI) disorders. The Phase 1 clinical trial is designed to test the safety, tolerability and pharmacokinetics of PF-04548043 in healthy subjects. In December 2006, Kosan and Pfizer established a worldwide license agreement for Kosan's motilin agonist program, including KOS-2187 and related compounds, in a transaction potentially valued at $250 million for the successful development and commercialization of PF-04548043 for one indication as well as royalties on worldwide sales.

"Kosan today has four advancing clinical programs, underscoring the increasing value of our development pipeline," said Robert G. Johnson, Jr., M.D., Ph.D., Kosan's President and Chief Executive Officer. "Consistent with Kosan's focus on oncology, we successfully out-licensed KOS-2187 and our motilin receptor agonist program to Pfizer, a company with a strong gastrointestinal capability that could best exploit its therapeutic and commercial potential. We appreciate Pfizer's commitment to the development and potential commercialization of this promising prokinetic compound and look forward to its rapid advancement through the clinic."

About PF-04548043 and Motilin Receptor Agonists

Motilin, a hormone secreted by the small intestine, stimulates gastrointestinal motility (movement). The activity of motilin is mediated through the G-protein coupled
'/>"/>

SOURCE Kosan Biosciences Incorporated

Copyright©2007 PR Newswire.

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
2. Human Genome Sciences Reports Growing Evidence That Its TRAIL Receptor Antibodies Have Significant Potential in the Treatment of a Broad Range of Cancers
3. First Controlled Large-Scale Intervention Angiotensin Receptor Blocker (ARB) Trial in a Japanese Population, JIKEI HEART Study Demonstrates Significant Reduction in Blood Pressure and Protection of Organs with Valsartan
4. Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine
5. Portola Pharmaceuticals Presents Positive Phase I Data of Its ADP Receptor Antagonist at the American College of Cardiology
6. Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
7. Weight Management is Not Enough for Cannabinoid Type 1 (CB1) Receptor Antagonists to Become a Commercial Success
8. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
9. GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets Phase II Study Endpoints of Immunogenicity and Safety Compared to Licensed Vaccines
10. CytRx Announces RNAi Delivery Nanoparticle Technology Exclusively Licensed to Subsidiary, RXi Pharmaceuticals, Described in Peer-Reviewed Journal
11. Mode of Action of EpiCept-Licensed Cancer Compound Profiled at AACR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... Calif. , May 21, 2013 Abaxis, ... blood analysis systems, announced today that Martin ... at the Stifel Annual Dental & Veterinary Conference on ... conference will be held at Le Parker Meridien Hotel ... About Abaxis Abaxis develops, manufactures, markets ...
(Date:5/21/2013)... YORK , May 21, 2013 /PRNewswire/ ... research report is available in its catalogue: ... Regulatory and Reimbursement Scenario for Medical Devices ... http://www.reportlinker.com/p01188015/Changing-Regulatory-and-Reimbursement-Scenario-for-Medical-Devices-in-the-US-Market.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging   Changing ... in the US Market   ...
(Date:5/21/2013)... MONROVIA, Calif. , May 21, 2013 ... leading developer, manufacturer and marketer of minimally invasive ophthalmic ... upcoming investor conferences to review the Company,s recent financial ... STAAR Surgical will present at the 38 ... Boston at the Westin Waterfront ...
Breaking Medicine Technology:Abaxis, Inc. to Present at the Stifel Annual Dental & Veterinary Conference 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 2Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 3Changing Regulatory and Reimbursement Scenario for Medical Devices in the US Market 4STAAR Surgical To Present At Upcoming Investor Conferences 2
... Poster 16LB -- Late-breaking Novo Nordisk (NVO) extension data presented today ... that once-daily Victoza ® in combination with metformin produced sustained and significantly ... ® plus metformin at 52 weeks. , ... Key findings from the study include: , ...
... JACKSONVILLE, Fla. , June 28 ... of its SurgiSteer™ laparoscopic instruments.  Developed from licensed ... will exploit single port laparoscopic surgery with its ... and Endo Scissors, available in both free and ...
Cached Medicine Technology:New Data Demonstrates Victoza® (liraglutide [rDNA] injection) Provided Superior and Sustained Blood Sugar Control and Weight Reduction Compared to Januvia® (sitagliptin) at One Year 2New Data Demonstrates Victoza® (liraglutide [rDNA] injection) Provided Superior and Sustained Blood Sugar Control and Weight Reduction Compared to Januvia® (sitagliptin) at One Year 3New Data Demonstrates Victoza® (liraglutide [rDNA] injection) Provided Superior and Sustained Blood Sugar Control and Weight Reduction Compared to Januvia® (sitagliptin) at One Year 4New Data Demonstrates Victoza® (liraglutide [rDNA] injection) Provided Superior and Sustained Blood Sugar Control and Weight Reduction Compared to Januvia® (sitagliptin) at One Year 5New Data Demonstrates Victoza® (liraglutide [rDNA] injection) Provided Superior and Sustained Blood Sugar Control and Weight Reduction Compared to Januvia® (sitagliptin) at One Year 6New Data Demonstrates Victoza® (liraglutide [rDNA] injection) Provided Superior and Sustained Blood Sugar Control and Weight Reduction Compared to Januvia® (sitagliptin) at One Year 7Steerable Technologix LLC Announces Release of SurgiSteer Laparoscopic Instruments 2
(Date:5/21/2013)... HealthDay Reporter , , MONDAY, May 20 (HealthDay News) ... drowsy run a higher risk of getting into car ... up on missed sleep on weekends puts them in ... "This is another challenge to adolescents that comes ... director and founder of the Center for Injury Research ...
(Date:5/21/2013)... of non-small cell lung cancer (NSCLC) in U.S. hospitals ... according to a new study., "In most patients, the ... is surgery," said researcher Jayanth Adusumalli, MBBS, of the ... study of more than 1,200,000 patients diagnosed with NSCLC ... we found statistically significant racial disparities in the surgical ...
(Date:5/21/2013)... an Alpha-1 proteinase inhibitor (A1-PI), a naturally occurring ... protects the lung,s elasticity, is effective in slowing ... antitrypsin deficiency (AATD), a life-threatening genetic disorder, according ... American Thoracic Society International Conference. , The study ... of lung tissue as measured by computed tomography ...
(Date:5/21/2013)... 2013 According to the Los ... to make possession of controlled substances (heroin, cocaine, crystal ... offense. MacGregor & Collins Orange County criminal lawyers believe ... overcrowding as well as improving rehabilitation rates amongst controlled ... bill met a great deal of resistance from the ...
(Date:5/21/2013)... 21, 2013 The first ever over-the-counter ... Seal, Anti Itchbalm, is ready to come to pharmacies ... and effective product which will help attract more customers ... community. , US Organic Group Corp. has developed Anti ... can be safely used on both adults and children, ...
Breaking Medicine News(10 mins):Health News:Weekend 'Catch-Up' Sleep May Cut Young Drivers' Crash Risk 2Health News:Treatment with A1-PI slows the progression of emphysema in Alpha-1 antitrypsin deficiency 2Health News:Treatment with A1-PI slows the progression of emphysema in Alpha-1 antitrypsin deficiency 3Health News:New Drug Bill to Lower Penalties for Possession of Controlled Substances Gains Support from Criminal Lawyers 2Health News:First Ever Over-the-Counter Organic Anti-Itch Ointment Developed by US Organic Group Corp. 2
... that craving a cigarette while performing a cognitive task ... wandering, but also makes that person less likely to ... The paper, titled "Out for a Smoke: The Impact ... the first evidence that craving disrupts an individual,s meta-awareness, ...
... , INDIANAPOLIS, Dec. 7 ... the availability of a smaller insulin vial, the first in the ... with diabetes being treated in a hospital. , The new smaller ... origin]) and Humulin® R-U100 (regular insulin human injection, ...
... , HORSHAM, Pa., Dec. 7 ... TEVA ), today announced the publication of four articles ... Journal of Allergy and Clinical Immunology (JACI), providing ... small airways in the understanding and treatment of asthma. This ...
... new University of Pittsburgh study reveals that craving a ... the chances of a person,s mind wandering, but also ... or her mind has wandered. The paper, titled ... on Zoning Out During Reading," provides the first evidence ...
... ... Hunt, a range of experts and healthcare leaders will focus on sharing best practices ... industries will discuss lessons learned in developing functional health information exchanges which provide safer ... ...
... who have been infected with West Nile virus may ... initial infection, potentially leading to kidney problems. The research, ... Journal of Infectious Diseases , is now available ... West Nile virus was first detected in the United ...
Cached Medicine News:Health News:Pitt study suggests craving hinders comprehension without your realizing it 2Health News:Lilly Announces the First 300-unit Vial of Insulin 2Health News:Lilly Announces the First 300-unit Vial of Insulin 3Health News:Lilly Announces the First 300-unit Vial of Insulin 4Health News:Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 2Health News:Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 3Health News:Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 4Health News:Data Published in Leading Respiratory Journal Reinforce Importance of Small Airways In Asthma Management 5Health News:Pitt study suggests craving hinders comprehension without you realizing it 2Health News:Orion Health Participates in International Forum to Break Down Barriers for Health Information Exchange 2Health News:Orion Health Participates in International Forum to Break Down Barriers for Health Information Exchange 3Health News:West Nile virus infection may persist in kidneys years after initial infection 2Health News:West Nile virus infection may persist in kidneys years after initial infection 3
... is a state-of-the-art hair reduction and ... specially designed for use within a ... features and economy in a single ... treatment of unwanted hair, photo rejuvenation ...
... perfect mix of powerful, versatile, and innovative ... Palomar StarLux® Pulsed Light and Laser System.,With ... compact base unit so theres no ... treatments., You can choose among Laser, Intense ...
Perfect for physicians who prefer a Heavier and Longer tubing, permitting them maximum access around the OR table. 12 feet in length Sizes availabe to fit any vacuum canisters...
... Pump provides optimum flow rate ... Operates on any voltage worldwide. ... safety Interlock and easy load ... Double Spike Tubing, Dual Pneumatic ...
Medicine Products: